A $10,000 investment in Vanguard's Health Care ETF (VHT) made in 2004 grew to $93,915 by 2026, reflecting an 839% total return with dividends reinvested. The fund's low expense ratio of 0.09% and broad exposure across large, mid, and small-cap healthcare companies make it a strong long-term option. While alternatives like XLV, IHI, and IBB offer narrower focuses with higher fees and different risk profiles, VHT suits investors seeking diversified healthcare exposure at minimal cost. Investors should consider sector risks and how the fund fits within their overall portfolio strategy.
XLV, a healthcare ETF mentioned as an alternative to Vanguard's VHT, trades at USD 184.84 on Pluang with a 1-day gain of 0.43% as of Nov 01, 2026 03:21 WIB. The fund holds a market cap of $48.47 billion and sees active buying with 100% buy orders and no sell orders. This current market activity highlights ongoing investor interest in healthcare sector ETFs alongside the long-term growth story of VHT.
Fidelity's Health Care ETF (FHLC) and the Health Care Select Sector SPDR ETF (XLV) both track the health care sector but differ significantly in holdings and biotech exposure. FHLC holds 337 companies including many small and mid-size biotechs, while...
Regeneron's shares surged 13.55% following a strong third-quarter earnings report that beat revenue and earnings expectations. This rise positively impacted health care ETFs like XLV, IBB, and XBI, which hold Regeneron shares, contributing to their g...
